作者
WA Van der Zwan, Tessa Brabander, BLR Kam, JJM Teunissen, RA Feelders, Johannes Hofland, EP Krenning, WW De Herder
发表日期
2019/3/1
期刊
European journal of nuclear medicine and molecular imaging
卷号
46
页码范围
704-717
出版商
Springer Berlin Heidelberg
简介
Purpose
Therapy with [177Lu-DOTA,Tyr3]octreotate is effective in patients with grade I/II metastasized and/or inoperable bronchial neuroendocrine tumour (NET) or gastroenteropancreatic NET (GEP-NET). In this study, we investigated the efficacy and safety of salvage treatment with [177Lu-DOTA,Tyr3]octreotate.
Methods
Patients with progressive bronchial NET or GEP-NET were selected for re-(re)treatment if they had benefited from initial peptide receptor radionuclide therapy (I-PRRT) with a minimal progression-free survival (PFS) of 18 months. Patients received an additional cumulative dose of 14.8 GBq of [177Lu-DOTA,Tyr3]octreotate over two cycles per retreatment with PRRT (R-PRRT) or re-retreatment with PRRT (RR-PRRT).
Results
The safety and efficacy analyses included 181 patients and 168 patients …
学术搜索中的文章
WA Van der Zwan, T Brabander, BLR Kam… - European journal of nuclear medicine and molecular …, 2019